Aeolus Pharmaceuticals, which closed recently on new financing, is bringing in a consulting firm to help it evaluate “strategic opportunities,” Aeolus said Thursday.

ThinkEquity Partners, an institutional investment firm, was brought in to “further strengthen and enhance the breadth of long-term strategic options that may be available to Aeolus as we advance our very exciting compounds through the clinical testing process,” said Aeolus CEO Richard Burgoon, Jr.
Aeolus is focused on drugs to treat neurological disorders such as Lou Gehrig’s disease.

Aeolus said it would receive $2.5 million in financing from Xmark Opportunity Funds earlier this week.